{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-037861","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.723732+00:00","generated_at":"2026-06-03T04:19:25.124608+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Citius Pharma raises ~$15M in registered direct offering of common stock and warrants","bullets":["Sold 21.43M shares and warrants to buy 21.43M shares at $0.70/combined unit.","Warrants exercisable at $0.75/share from 6 months after issuance, expire in 5 years.","Gross proceeds ~$15M; net proceeds ~$13.8M after placement agent fees and expenses.","Proceeds for general corporate purposes, including pre-clinical/clinical development and working capital.","Offering closed April 30, 2024; H.C. Wainwright acted as exclusive placement agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-037861","json":"https://secwatch.observer/filing/0001213900-24-037861.json","markdown":"https://secwatch.observer/filing/0001213900-24-037861.md","text":"https://secwatch.observer/filing/0001213900-24-037861.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024037861/0001213900-24-037861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024037861/ea0204892-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T04:19:25.124608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"120efcd9c395d30ed290e8b07d73338405d28adb","claim":"Citius Pharmaceuticals, Inc. entered into Purchase Agreement with certain institutional investors (effective 2024-04-25).","evidence_excerpt":"On April 25, 2024, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 21,428,574 shares of the Company’s common stock, par value $0.001 per share (the “Shares”) and warrants (the “Warrants”) to purchase up to 21,428,574 shares of common stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024037861/0001213900-24-037861-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Effective","value":"2024-04-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}